Effects of Selective Serotonin Reuptake Inhibitor Therapy on Endothelial Function and Inflammatory Markers in Patients With Coronary Heart Disease
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
We investigated the effect of sertraline on inflammation and endothelial function in patients with coronary heart disease (CHD) and symptoms of depression. One hundred patients with CHD and depression were randomized in a double-blind fashion to receive sertraline or a placebo. We measured symptoms of depression (Beck Depression Inventory (BDI) score), levels of inflammatory markers (C-reactive protein (CRP) and interleukin-6 (IL-6)), and flow-dependent endothelium-mediated dilation (FMD) before and after 20 weeks of treatment. Sertraline treatment significantly reduced the BDI score as compared with both baseline and placebo. Levels of CRP and IL-6 also decreased after 20 weeks of sertraline treatment, whereas they did not significantly change in the placebo group. There was a significant improvement in FMD in patients on sertraline treatment, whereas there was no change in FMD in the placebo group. Sertraline improves endothelial function and reduces inflammatory markers in patients with CHD and symptoms of depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sertraline treatment of major depression in patients with acute MI or unstable angina
Glassman, A. H. (2002) · JAMA · doi:10.1001/jama.288.6.701 · Cited by 1,414
Nicholson, A., Kuper, H., & Hemingway, H. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl338 · Cited by 1,353
van Melle, J. P., de Jonge, P., Spijkerman, T. A., Tijssen, J. G. P., Ormel, J., van Veldhuisen, D. J., van den Brink, R. H. S., & van den Berg, M. P. (2004) · Psychosomatic Medicine · doi:10.1097/01.psy.0000146294.82810.9c · Cited by 1,034
Wulsin, L. R., & Singal, B. M. (2003) · Psychosomatic Medicine · doi:10.1097/01.psy.0000058371.50240.e3 · Cited by 730
PSYCHONEUROENDOCRINOLOGY OF DEPRESSION
Plotsky, P. M., Owens, M. J., & Nemeroff, C. B. (1998) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70006-x · Cited by 672
Pace, T. W. W., Hu, F., & Miller, A. H. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2006.08.009 · Cited by 621
Ford, D. E., & Erlinger, T. P. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.9.1010 · Cited by 544
Neuroendocrinological mechanisms of actions of antidepressant drugs
Schüle, C. (2007) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2006.01516.x · Cited by 167
Cited by
Hannestad, J., DellaGioia, N., & Bloch, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.132 · Cited by 914
Depression and cardiac disease: epidemiology, mechanisms, and diagnosis.
Huffman, J. C., Celano, C. M., Beach, S. R., Motiwala, S. R., & Januzzi, J. L. (2013) · Cardiovascular Psychiatry and Neurology · doi:10.1155/2013/695925 · Cited by 445
Heartache and heartbreak—the link between depression and cardiovascular disease
Nemeroff, C. B., & Goldschmidt-Clermont, P. J. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.91 · Cited by 424
Depression and Cardiac Disease: A Review
Celano, C. M., & Huffman, J. C. (2011) · Cardiology in Review · doi:10.1097/crd.0b013e31820e8106 · Cited by 320
Andrade, C., Sandarsh, S., Chethan, K. B., & Nagesh, K. S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09r05786blu · Cited by 302
Rutledge, T., Redwine, L. S., Linke, S. E., & Mills, P. J. (2013) · Psychosomatic Medicine · doi:10.1097/psy.0b013e318291d798 · Cited by 277
Hiles, S. A., Baker, A. L., de Malmanche, T., & Attia, J. (2012) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.06.001 · Cited by 274
“Additionally, often in the context of general medical illness, randomized controlled trials have indicated that psychological or antidepressant treatment for depression may reduce pro-inflammatory markers and improve immune functioning, administration of antidepressants can reduce depression induced by treatment with…”
BackgroundChauvet-Gelinier, J.-C., & Bonin, B. (2017) · Annals of Physical and Rehabilitation Medicine · doi:10.1016/j.rehab.2016.09.002 · Cited by 252
Depression and Cardiovascular Disorders
Whooley, M. A., & Wong, J. M. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185526 · Cited by 241
“In fact, a double-blind study randomized 100 patients to sertraline or placebo for 20 weeks and found that the group receiving sertraline had improvements in depression and reductions in inflammatory biomarkers, including CRP, IL-6, and fibrinogen (Pizzi et al. 2009).”
BackgroundPizzi, C., Rutjes, A. W. S., Costa, G. M., Fontana, F., Mezzetti, A., & Manzoli, L. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.11.017 · Cited by 203
Self-citationPsychopharmacology and Cardiovascular Disease
Piña, I. L., Di Palo, K. E., & Ventura, H. O. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.458 · Cited by 126
Depression and cardiovascular disease: an update on how course of illness may influence risk
Fiedorowicz, J. G. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0492-6 · Cited by 103
“In another meta-analysis, IL-6 levels only appeared reduced in trials of selective serotonin reuptake inhibitors (SSRIs), suggesting the effects may be treatment specific [77].”
BackgroundInfluentialPark, M., Newman, L. E., Gold, P. W., Luckenbaugh, D. A., Yuan, P., Machado-Vieira, R., & Zarate, C. A. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.09.025 · Cited by 93
“Furthermore, antidepressant-induced remission of depressive symptoms has also been associated with significant decreases in pro-inflammatory cytokine levels (Leo et al., 2006, Pizzi et al., 2009).”
BackgroundAnti-depressant medication use and C-reactive protein: Results from two population-based studies
Hamer, M., Batty, G., Marmot, M. G., Singh-Manoux, A., & Kivimäki, M. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.09.013 · Cited by 71
Depression and subsequent risk for incident rheumatoid arthritis among women
Sparks, J. A., Malspeis, S., Hahn, J., Wang, J., Roberts, A. L., Kubzansky, L. D., & Costenbader, K. H. (2021) · Arthritis Care & Research · doi:10.1002/acr.24441 · Cited by 53
“In a randomized trial, individuals assigned to the antidepressant sertraline (a selective serotonin reuptake inhibitor [SSRI]) had significantly lowered serum IL-6 and CRP levels compared to those assigned placebo, demonstrating that treating depression may lower systemic inflammation (22).”
BackgroundAntidepressant use and risk of coronary heart disease: meta‐analysis of observational studies
Oh, S., Kim, J., Myung, S., Hwang, S., & Yoon, D. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12383 · Cited by 40
Metadata
- Authors
- Pizzi, C., Mancini, S., Angeloni, L., Fontana, F., Manzoli, L., & Costa, G. M.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2009-07-29
- Volume
- 86
- Issue
- 5
- Pages
- 527-532
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2009923332
- Cited by
- 146
- References
- 9
- FWCI
- 6.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.